Compare WAT & RMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WAT | RMD |
|---|---|---|
| Founded | 1958 | 1989 |
| Country | United States | United States |
| Employees | N/A | 10600 |
| Industry | Biotechnology: Laboratory Analytical Instruments | Medical/Dental Instruments |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 29.3B | 33.2B |
| IPO Year | 1996 | N/A |
| Metric | WAT | RMD |
|---|---|---|
| Price | $303.90 | $226.89 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 17 | 10 |
| Target Price | ★ $386.38 | $293.70 |
| AVG Volume (30 Days) | ★ 999.3K | 848.9K |
| Earning Date | 05-05-2026 | 04-22-2026 |
| Dividend Yield | N/A | ★ 1.05% |
| EPS Growth | ★ 0.47 | N/A |
| EPS | ★ 10.76 | N/A |
| Revenue | ★ $3,165,286,000.00 | N/A |
| Revenue This Year | $104.66 | $10.58 |
| Revenue Next Year | $10.53 | $7.38 |
| P/E Ratio | $28.06 | ★ $25.61 |
| Revenue Growth | ★ 6.99 | N/A |
| 52 Week Low | $275.05 | $199.92 |
| 52 Week High | $414.15 | $293.81 |
| Indicator | WAT | RMD |
|---|---|---|
| Relative Strength Index (RSI) | 41.83 | 30.41 |
| Support Level | $281.62 | N/A |
| Resistance Level | $308.14 | $260.21 |
| Average True Range (ATR) | 8.63 | 5.28 |
| MACD | 2.99 | -1.26 |
| Stochastic Oscillator | 63.96 | 21.07 |
Waters sells liquid chromatography, mass spectrometry, and thermal analysis tools. These analytical instruments provide essential information on various products, such as their molecular structures and physical properties, to help clients enhance the health and well-being of end users. In early 2026, Waters merged with BD's life science and diagnostics business, which increased its concentration in diagnostics (versus none now) and discovery-related life science tools.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.